The DOI matches its Crossref record.
The cost burden of multiple sclerosis in the United States: a systematic review of the literature
Abstract
OBJECTIVES: To estimate average annual cost per multiple sclerosis (MS) patient in the US using published estimates from the literature. METHODS: A search was performed of English-language literature published between 2007 and June 2012 in PubMed and Embase using the term 'multiple sclerosis' and the subject heading 'healthcare costs'. Included articles were primary studies with MS cost figures that could be converted to per patient per year values. Costs were inflated to 2011 dollars using the medical component of the Consumer Price Index. RESULTS: Fifteen studies met the inclusion criteria. Eight presented only direct cost calculations; the remaining seven presented estimates of total cost, broken down into direct and indirect costs. Total all-cause healthcare costs for MS as reported by studies that included direct and indirect costs ranged from $8528-$54,244 per patient per year. On average, direct costs comprised 77% (range 64-91%) of total costs. Prescription medications accounted for the majority of direct costs. On average, indirect costs comprised 23% (range 9-36%) of total costs. Compared with direct all-cause medical costs for other chronic conditions reported in the literature, MS ranked second behind congestive heart failure. LIMITATIONS: Data sources in these studies were dated, ranging from 1999-2008, and therefore do not include some of the newer, more costly therapies. In addition, this review does not include either assessment of the decrements in quality-of-life associated with MS or costs associated with increasing levels of disability or early retirement. Furthermore, variations in study designs, populations, methodologies, and cost inputs preclude more precise cost estimates. CONCLUSIONS: MS is a costly chronic disease. Further research is needed to understand: costs by MS type, costs associated with increasing disability and early retirement, and the potential impact of new treatments expected to launch in coming years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Ma, V. Y., Chan, L., & Carruthers, K. J. (2014) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2013.10.032 · Cited by 836
Neural recording and modulation technologies
Chen, R., Canales, A., & Anikeeva, P. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.93 · Cited by 655
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Multiple sclerosis prevalence in the United States commercially insured population
Dilokthornsakul, P., Valuck, R. J., Nair, K. V., Corboy, J. R., Allen, R. R., & Campbell, J. D. (2016) · Neurology · doi:10.1212/wnl.0000000000002469 · Cited by 273
Metadata
- Authors
- Adelman, G., Rane, S. G., & Villa, K. F.
- Venue
- Journal of Medical Economics
- Publisher
- Informa UK Limited
- Published
- 2013-03-07
- Volume
- 16
- Issue
- 5
- Pages
- 639-647
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W2067673653
- Cited by
- 205
- References
- 0
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The cost burden of multiple sclerosis in the United States: a systematic review of the literature. https://app.cochat.ai/papers/10.3111/13696998.2013.778268
- The paper
- Adelman, G., Rane, S. G., & Villa, K. F. (2013). The cost burden of multiple sclerosis in the United States: a systematic review of the literature. Journal of Medical Economics. https://doi.org/10.3111/13696998.2013.778268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.